Jazz Pharmaceuticals

Human brain
#Brain cancer #FDA #Jazz Pharmaceuticals #Oncology

FDA approves first treatment for rare type of glioma

The US Food and Drug Administration (FDA) has granted accelerated approval for Modeyso (dordaviprone) for the treatment of patients one year of age and older with diffuse midline glioma harbouring an H3 K27M mutation with progressive disease following prior therapy.  The FDA has stated that continued approval for this indication… Read More

#News #Regulatory

Biliary tract
#CHMP #European Medicines Agency #Jazz Pharmaceuticals #Oncology

CHMP issues positive opinion for biliary tract cancer treatment

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the conditional marketing authorisation of the EU’s first HER2-targeted therapy for biliary tract cancer (BTC).  Zanidatamab is an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody.  It is recommended as… Read More

#News #Regulatory

FDA
#Bispecific Antibodies #FDA #Jazz Pharmaceuticals #Oncology

Bispecific antibody gets accelerated FDA approval for biliary tract cancer

The Food and Drug Administration (FDA) has granted accelerated approval to Jazz Pharmacuticals’ zanidatamab-hrii (Ziihera) a bispecific HER2-directed antibody.  It is approved for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.  The FDA also approved VENTANA PATHWAY anti-HER-2/neu (4B5) Rabbit… Read More

#News #Regulatory

European Commission
#Chemotherapy #European Commission #Jazz Pharmaceuticals #Leukaemia #Paediatrics

EC approves Erwinia-derived asparaginase for leukaemia

The European Commission (EC) has granted marketing authorisation for Jazz Pharmaceuticals’ Enrylaze as part of a multi-agent regimen for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). The treatment is approved in adult and paediatric patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enrylaze, approved as Rylaze… Read More

#News #Regulatory

Leukaemia
#Blood cancer #Cancer research #CHMP #EMA #European Commission #Jazz Pharmaceuticals #Leukaemia #Oncology

EU positive opinion for acute lymphoblastic leukaemia drug

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorisation of JZP458 (a recombinant Erwinia asparaginase or crisantaspase). It has been recommended for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic… Read More

#News #Regulatory